4-[2-(4-trifluoromethyl-phenyl)-benzo[1,3]dioxol-2-yl]-piperidine | 856936-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 4-[2-(4-trifluoromethyl-phenyl)-benzo[1,3]dioxol-2-yl]-piperidine
• 英文别名: 4-[2-[4-(trifluoromethyl)phenyl]-1,3-benzodioxol-2-yl]piperidine
• CAS: 856936-16-8
• 化学式: C₁₉H₁₈F₃NO₂
• 分子量: 349.353
• InChiKey: JOWPEILEYQYKGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[2-(4-trifluoromethyl-phenyl)-benzo[1,3]dioxol-2-yl]-piperidine 在 dimethyl sulfide borane 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-{4-[2-(4-Trifluoromethyl-phenyl)-benzo[1,3]dioxol-2-yl]-piperidin-1-yl}-butylamine
  参考文献：
  名称：

  Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

  摘要：

  A novel series of CCR5 antagonists were identified based on the redesign of Schering C. An SAR was established based on inhibition of CCR5 (RANTES) binding and these compounds exhibited potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.058
• 作为产物：
  描述：

  4-(4-(三氟甲基)苯甲酰基)哌啶-1-羧酸叔丁酯 、 邻苯二酚 在 对甲苯磺酸 作用下， 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂， 反应 47.0h， 生成 4-[2-(4-trifluoromethyl-phenyl)-benzo[1,3]dioxol-2-yl]-piperidine
  参考文献：
  名称：

  Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

  摘要：

  A novel series of CCR5 antagonists were identified based on the redesign of Schering C. An SAR was established based on inhibition of CCR5 (RANTES) binding and these compounds exhibited potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.058

文献信息

• Chemokine receptor binding compounds
  申请人：Zhou Yuanxi

  公开号：US20050277670A1

  公开（公告）日：2005-12-15

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

  本发明涉及化学因子受体结合化合物、制药组合物及其使用。更具体地，本发明涉及化学因子受体活性调节剂，优选为CCR5的调节剂。这些化合物表现出对人类免疫缺陷病毒（HIV）感染靶细胞的保护作用。
• CHEMOKINE RECEPTOR BINDING COMPOUNDS
  申请人：ANORMED INC.

  公开号：EP1708703A2

  公开（公告）日：2006-10-11
• EP1708703A4
  申请人：——

  公开号：EP1708703A4

  公开（公告）日：2008-04-09
• US7491735B2
  申请人：——

  公开号：US7491735B2

  公开（公告）日：2009-02-17
• [EN] CHEMOKINE RECEPTOR BINDING COMPOUNDS<br/>[FR] COMPOSES DE LIAISON AUX RECEPTEURS DE LA CHEMOKINE
  申请人：ANORMED INC

  公开号：WO2005059107A2

  公开（公告）日：2005-06-30

  The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).